oxidopamine has been researched along with Diabetes Mellitus, Type 1 in 5 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "During the early phase of scar formation/healing, the density of GAP43/nestin(+) fibres innervating the peri-infarct/infarct region was significantly increased, whereas neurofilament-M/nestin(+) fibres were absent." | 1.39 | The neurogenic response of cardiac resident nestin(+) cells was associated with GAP43 upregulation and abrogated in a setting of type I diabetes. ( Calderone, A; Chabot, A; Duquette, N; Hertig, V; Meus, MA, 2013) |
| "Mice with autoimmune diabetes had an impaired glucagon response to sympathetic nerve activation, whereas those with non-autoimmune diabetes did not." | 1.35 | Loss of islet sympathetic nerves and impairment of glucagon secretion in the NOD mouse: relationship to invasive insulitis. ( Figlewicz, DP; Hackney, DJ; LeBoeuf, R; Mei, Q; Mundinger, TO; Taborsky, GJ, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chabot, A | 1 |
| Meus, MA | 1 |
| Hertig, V | 1 |
| Duquette, N | 1 |
| Calderone, A | 1 |
| Taborsky, GJ | 4 |
| Mei, Q | 4 |
| Hackney, DJ | 1 |
| Figlewicz, DP | 2 |
| LeBoeuf, R | 1 |
| Mundinger, TO | 4 |
| Lernmark, A | 2 |
| Lernmark, K | 1 |
5 other studies available for oxidopamine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
The neurogenic response of cardiac resident nestin(+) cells was associated with GAP43 upregulation and abrogated in a setting of type I diabetes.
Topics: Animals; Cicatrix; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Fibrosis; GAP-43 Prot | 2013 |
Loss of islet sympathetic nerves and impairment of glucagon secretion in the NOD mouse: relationship to invasive insulitis.
Topics: Animals; Cyclophosphamide; Diabetes Mellitus, Type 1; Female; Glucagon; Hyperinsulinism; Islets of L | 2009 |
Early, selective, and marked loss of sympathetic nerves from the islets of BioBreeder diabetic rats.
Topics: Animals; Antibodies; Diabetes Mellitus, Type 1; Female; Islets of Langerhans; Male; Membrane Glycopr | 2002 |
Impaired glucagon response to sympathetic nerve stimulation in the BB diabetic rat: effect of early sympathetic islet neuropathy.
Topics: Animals; Diabetes Mellitus, Type 1; Diabetic Neuropathies; Electric Stimulation; Epinephrine; Female | 2003 |
Increased galanin expression in the celiac ganglion of BB diabetic rats.
Topics: Animals; Diabetes Mellitus, Type 1; Disease Models, Animal; Galanin; Ganglia, Sympathetic; Gene Expr | 2006 |